Our famiy office has invested in a company that has created a unique and highly innovative patented technology based on biologically-active materials manufactured from allogenic human blood plasma. These Plasma-based Bioactive Materials (PBMs) contain highly concentrated natural regenerative factors that promote healing and reduce infections in multiple clinical settings. As a result, they help lower healthcare costs.

The company has patented a process which fine-tunes the release of active biologics on a staged basis (days/weeks/months) when the body needs them most to accelerate healing.

Our family office has been the lead investor in this company since 2011, and have participated in every round (Series A & B) as well as leading this Convertible Note which is intended to get the company to an IPO in 2019.  The company anticipates IND approval for it's Phase III trial in January after which it will use the proceeds of the IPO to fund the Phase III trial.  (US and EU)  The price and terms of this deal are highly attractive and this company is poised to disrupt large addressable markets with its technology.  Most of the management team has come out of Johnson and Johnson, and the technology came out of Carnegie Mellon.

There is approximately $3M open of this $6M round which will close before the end of the year.  Please contact us to receive information about this opportunity.